Are you curious about pertuzumab and how it works in the medical field? Do you want to learn everything there is to know about this powerful medication, including its indications, dosing, and side effects? Look no further! In this comprehensive guide, we will break down all the information you need to understand pertuzumab. From breast cancer treatment to its unique mechanism of action, we've got you covered.
Pertuzumab (brand name Perjeta) is a prescription medication used to treat breast cancer. It’s a type of targeted therapy that works by interfering with the growth and spread of cancer cells. Pertuzumab is given as an infusion into a vein (IV). It’s usually given with other cancer medications.
Common side effects of pertuzumab include nausea, vomiting, diarrhea, constipation, headache, tiredness, low blood cell counts, and infusion-related reactions. Serious side effects can also occur. Pertuzumab can interact with other medications, herbs, or vitamins you might be taking.
Pertuzumab is a monoclonal antibody that targets the HER2 protein. The HER2 protein is found on the surface of some breast cancer cells. About 1 out of every 5 breast cancers is HER2-positive. These types of breast cancers tend to grow and spread more quickly than other types of breast cancer. Pertuzumab slows or stops the growth of HER2-positive breast cancer cells by binding to the HER2 protein and preventing it from working properly
Pertuzumab is a humanized monoclonal antibody that targets the HER2 protein. It is used in combination with other cancer treatments, such as trastuzumab and docetaxel, to treat HER2-positive breast cancer.
Pertuzumab can cause serious side effects, including heart problems, gastrointestinal problems, and infusion reactions.
Some common side effects of pertuzumab include nausea, vomiting, diarrhea, constipation, headache, fatigue, muscle pain, joint pain, and skin rash. These side effects usually go away after a few weeks of treatment.
Pertuzumab is a monoclonal antibody that works by targeting a protein called HER2, which is found on the surface of some cancer cells. By targeting this protein, pertuzumab can help to kill cancer cells or stop them from growing.
Like all medications, pertuzumab can cause side effects. The most common side effects of pertuzumab include:
• Nausea and vomiting
• Diarrhea
• Skin rash or itching
• Fatigue
• Headache
• Musculoskeletal pain
Less common side effects of pertuzumab include:
• Low blood counts (anemia, neutropenia, thrombocytopenia)
• Infusion-related reactions (fever, chills, nausea/vomiting, low blood pressure)
• Heart problems (heart failure, left ventricular ejection fraction [LVEF] decrease)
As a comprehensive guide to understanding pertuzumab, this article has discussed the drug's indications, dosing, and potential side effects. In summary, pertuzumab is indicated for use in the treatment of non-small cell lung cancer and HER2-positive breast cancer. It is given as an intravenous infusion every three weeks with or without other treatments depending on each patient’s individual case. The most common side effects associated with its use include fatigue, nausea ,and diarrhea.
1.
Remote monitoring can improve recovery from cancer surgery
2.
Intractable cancers may respond better to treatment when using new radiation and high-performance computing.
3.
A Win for AI in Cancer; 2025's Transformative Drugs; FDA Clarifies 'Underway' Trials
4.
Conditional EU Nod for Weekly Pill in Pediatric Glioma
5.
high response rate when using a bispecific antibody to treat R/R multiple myeloma.
1.
The Technological Revolution in Precision Oncology and Tumor Microenvironment Therapy
2.
The Role of the Oncology Pharmacist: From Treatment to Trials and Beyond
3.
Unlocking the Secrets of Neutrophils: Exploring Their Role in Immune Defense
4.
New Hope for Rectal Cancer Patients: Breakthrough Drug Shows Promising Results
5.
Unveiling the Mystery of Echinocyte: A Closer Look at the Unique Red Blood Cell
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Role of Nimotuzumab in Management of Nasopharyngeal Cancer
2.
The Landscape of First-Line Treatment for Urothelial Carcinoma- The Conclusion
3.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part III
4.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part IV
5.
An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation